News report 📈 Stocks 🌍 United States

InMed Pharmaceuticals Completes Merger, Rebrands to Mentari Therapeutics

InMed Pharmaceuticals completes its merger with Mentari Therapeutics, transitioning to the MTRI ticker symbol on November 9, 2026, while issuing non-transferable CVRs to eligible shareholders.

🕐 1 min read

1 assets impacted. Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: INM → 3/10 (65% confidence).

📊 Affected Assets (1)

INM
Neutral 🤖 65%
📅 Short-term 🌍 US · Explicit

The business combination of InMed Pharmaceuticals (INM) and Mentari Therapeutics closes today, November 6, 2026, and the shares switch name, symbol (INM to MTRI) and CUSIP (457637809 to 587157108) on Monday, November 9, 2026. The notice is administrative: it contains no valuation, deal price or financial figures, so the combined stock should trade on its own fundamentals after the change. Holders of record on November 5, 2026 also receive one non-transferable Contingent Value Right per share, whose value is uncertain and not quoted EX.

Catalysts
  • • Business combination closing Friday, November 6, 2026
  • • Name/symbol/CUSIP change to Mentari Therapeutics (MTRI, CUSIP 587157108) effective Monday, November 9, 2026
Risk Factors
  • • Closing is stated as 'subject to closing', so completion is not guaranteed
  • • The CVR is non-transferable and contingent, so its payout value is uncertain
▼ Show FAQ (2) ▲ Hide FAQ
What happens to my INM shares after the merger?

They become shares of the combined company, Mentari Therapeutics, trading under the new symbol MTRI with a new CUSIP (587157108) starting Monday, November 9, 2026. If you were a holder of record on November 5, 2026, you also receive one non-transferable Contingent Value Right per share.

Is this merger news good or bad for the stock price?

The notice itself changes nothing about the company's value — it confirms the change of control closes on November 6, 2026 and only renames and re-symbolizes the listing, so the immediate price effect is neutral.

🎯 Key Takeaways

  • InMed Pharmaceuticals (INM) rebrands to Mentari Therapeutics (MTRI) effective November 9, 2026.
  • Shareholders of record on November 5, 2026, receive one non-transferable CVR per share.
  • The transition involves a CUSIP change to 587157108 following the business combination.

📝 Executive Summary

InMed Pharmaceuticals (INM) has finalized its business combination with Mentari Therapeutics, effective November 6, 2026. Starting November 9, 2026, the company will trade under the new ticker symbol MTRI with a new CUSIP. Shareholders of record as of November 5, 2026, are entitled to one non-transferable Contingent Value Right (CVR) per share.

❓ FAQ

What happens to my INM shares after the merger?

They become shares of the combined company, Mentari Therapeutics, trading under the new symbol MTRI with a new CUSIP (587157108) starting Monday, November 9, 2026. If you were a holder of record on November 5, 2026, you also receive one non-transferable Contingent Value Right per share.

Is this merger news good or bad for the stock price?

The notice itself changes nothing about the company's value — it confirms the change of control closes on November 6, 2026 and only renames and re-symbolizes the listing, so the immediate price effect is neutral.